News in brief - October 2014 (updated)

Other new launches, licence changes and updates relevant to general practice.

Bemfola is available as a single-use, prefilled pen in a variety of doses and is administered by subcutaneous injection.
Bemfola is available as a single-use, prefilled pen in a variety of doses and is administered by subcutaneous injection.
  • Stirling Anglian has launched theiCal-d3, a high-dose, once-daily chewable tablet containing 2.5g calcium carbonate and 880iu vitamin D3.
  • A follitropin alfa biosimilar, Bemfola, is now available for the treatment of fertility disorders in men and women.
  • The triple antiretroviral combination tablet Triumeq (dolutegravir/abacavir/lamivudine) has been launched for the treatment of HIV in adults and children from 12 years.
  • A combination pack containing one mifepristone tablet and four misoprostol vaginal tablets (Medabon) is now available for the termination of pregnancy in women with ≤63 days' amenorrhoea.
  • Daraprim (pyrimethamine) is no longer licensed for malaria prophylaxis. It remains available for the treatment of toxoplasmosis in combination with a sulfonamide.
  • Ozurdex (dexamethasone intravitreal implant) has received an additional indication for the treatment of diabetic macular oedema in pseudophakic patients or if non-corticosteroid therapy is inadequate or unsuitable.

Follow MIMS on Twitter

Sign up for MIMS bulletins

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in